Group One Trading’s PharmaCyte Biotech PMCB Stock Holding History

Group One Trading’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-341,700	Closed	-$247K	–	8490
2025 Q4	$247K	Buy	+341,700	New	+$308K	﹤0.01%	4185
2024 Q2	–	Sell	-21,000	Closed	-$49.8K	–	7320
2024 Q1	$49.8K	Buy	+21,000	New	+$45.5K	﹤0.01%	4730
2023 Q4	–	Sell	-5,000	Closed	-$10.5K	–	8011
2023 Q3	$10.5K	Hold	5,000	–	–	﹤0.01%	6314
2023 Q2	$14.3K	Buy	5,000 +4,900	+4,900%	+$14.7K	﹤0.01%	6194
2023 Q1	$291	Sell	100 -14,500	-99%	-$42.6K	﹤0.01%	6966
2022 Q4	$42.6K	Buy	14,600 +100	+0.7%	+$286	﹤0.01%	5116
2022 Q3	$35K	Buy	14,500 +11,500	+383%	+$29.1K	﹤0.01%	5687
2022 Q2	$7K	Buy	+3,000	New	+$6.56K	﹤0.01%	6948
2022 Q1	–	Sell	-23,400	Closed	-$59K	–	8529
2021 Q4	$59K	Buy	23,400 +900	+4%	+$2.48K	﹤0.01%	6193
2021 Q3	$71K	Buy	+22,500	New	+$79.1K	﹤0.01%	6248

Other funds holding PMCB

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Group One Trading's PMCB Position: Q2 2026 in Review

Group One Trading reduced its PharmaCyte Biotech (PMCB) stake by 72% in Q2 2026, selling an estimated $967 and leaving 500 shares worth $385. The position accounts for ﹤0.01% of the portfolio, ranked #7332.

Group One Trading first reported a position in PMCB in Q2 2022 and has held it in 6 quarters since. The position peaked at $180K in Q3 2022. 28 funds tracked by Wall St. Rank hold PMCB as of Q2 2026.

Group One Trading held 500 shares of PharmaCyte Biotech worth $385 as of Q2 2026.
Group One Trading sold 1,285 PharmaCyte Biotech shares in Q2 2026, an estimated $967.
PharmaCyte Biotech made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #7332 holding.
Group One Trading first reported a position in PharmaCyte Biotech in Q2 2022 and has held it in 6 quarters since.
Group One Trading's PharmaCyte Biotech position peaked at $180K in Q3 2022.
28 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.